At Eisai, satisfying unmet medical needs and increasing the benefits healthcare provides to patients, their families, and caregivers is Eisai’s human health care (hhc) mission. We’re a growing pharmaceutical company that is breaking through in neurology and oncology, with a strong emphasis on research and development. Our history includes the development of many innovative medicines, notably the discovery of the world's most widely-used treatment for Alzheimer’s disease. As we continue to expand, we are seeking highly-motivated individuals who want to work in a fast-paced environment and make a difference. If this is your profile, we want to hear from you.
Eisai has been dedicated for decades to the pursuit of novel therapeutics to improve the lives of people suffering from dementia and their families. Recognizing the potential for human genetics, data sciences and precision chemistry to disrupt the drug discovery paradigm, Eisai launched the Eisai Center for Genetics Guided Dementia Discovery (G2D2) in 2019 to accelerate the discovery of innovative therapeutics. G2D2 is a unique drug discovery organization driven by a diverse group of passionate, dedicated and collaborative scientists committed to one goal: delivering breakthroughs for patients and their families. All Eisai employees, as part of the company’s human health care (hhc) mission, spend at least 1% of their working time with patients and families to ensure that the innovation we drive is based on an understanding of their real needs.
The predominant research focus at G2D2, driven by insights from human genetics, is immunodementia: targeting immune-related targets for dementia. At G2D2, we focus not only on how human genetics and other human biology data may identify and validate therapeutic targets with increased likelihood of success in clinical trials, but also how this data guides selection of the best approaches to design new therapeutics and the selection of strategies to deliver these therapeutics to the right patient at the right time. Recognizing the obvious alignment between human genetics and nucleic acid modalities, our precision chemistry strategy is to directly validate human biology hypotheses by utilizing our unique RNA targeting therapeutic platform. G2D2’s expertise in harnessing molecular complexity (stereochemistry and topology) to successfully discover and develop natural product based therapeutics has been applied to create an evolving unique nucleic acid immunotherapeutic platform that is being employed globally in multiple clinical and pre-clinical programs at Eisai.
G2D2’s cutting-edge 50,000-square-foot facility is strategically located in Cambridge, MA, to accelerate collaborations with leading research institutes in this world-class biotech hub. Our facility has been designed around an open-lab concept, enabling scientists with multi-disciplinary backgrounds to work together in a single integrated lab space. Our labs include state-of-the-art capabilities that support the variety of disciplines located at the site, including medicinal and process chemistry, in-vitro and in-vivo biology, microscopy, DMPK, drug safety, chemical and structural biology, automation and screening, and more. G2D2 is home to Eisai’s global capabilities in neurology discovery data science. G2D2 is also home to other global Eisai functions, including global health, DMPK, Safety, IP, oncology, thus providing a rich environment for cross-functional interaction. Our office is designed to foster an atmosphere of mission-driven and collaborative science, using new collaboration tools and technologies, and is being optimized to support a hybrid work environment.
At Eisai, we highly value both internal and external collaboration and pursue flexible research models with a range of external scientific partners to accelerate delivery of innovative medicines. To this end, the G2D2 facility includes the Eisai Innovation Center Biolabs, which provides space and infrastructure to start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.
Job Description – Genetic Epidemiologist, Neurology Business Group
G2D2 is home to Eisai’s Neurology Human Genetics and Computational Neurobiology teams. Members of these teams have the opportunity to perform foundational data science research that impacts Eisai’s entire neurology discovery portfolio across Eisai’s four worldwide discovery sites in the US, the UK, and Japan. The Genetic Epidemiologist will be a key member of the Human Genetics team and will have specific responsibilities for accessing and analyzing large population-based and disease-relevant cohorts with genomics and other multi-faceted datatypes. In addition, they will provide and implement recommendations for novel or existing technologies and analytic methods to improve experimental design and inform decision making. While the focus is expected to be on impacting the discovery process, this position will also serve as a subject matter expert for genetics within neurology, providing expert scientific guidance to impact neurology-related translational science and clinical development.
The Genetic Epidemiologist will join an existing (and evolving) human genetics group at G2D2 and will encounter a corporate culture that is very motivated to apply human genetics and other data-driven approaches to R&D at every level of the organization.
Contribute to the human genetics team’s effort to apply human genetics to impact program and portfolio decision-making across Eisai’s global Neurology Discovery sites, including target identification, target validation, biomarker discovery, and patient stratification strategies.
Work with the human genetics team to identify, initiate, and execute collaborations with academic, biotech, and other pharma partners to produce insights capable of impacting program and portfolio decision-making.
Collaborate with colleagues in Clinical Research to conduct exploratory genome-wide genotyping/sequencing and genetic analysis of Eisai’s neurology clinical trials.
Provide human genetics support to local and global stakeholders in Discovery Research, Translational Research, Clinical Research, and Commercial functions, specifically focusing on large-scale data-rich resources such as biobanks or EHR-based systems
Keep up to date on the latest science related to genotype-phenotype relationships including genetic risk scores, GWAS, PheWAS, meta-analyses, and gene burden tests.
Benchmark novel statistical and computational approaches for population-scale genetic data analysis; develop or bring new tools in house.
Collaborate with colleagues in Informatics and IT to assess needs and develop computational resources for conducting genetic analysis and interpretation of results.
Publish/present on key findings as appropriate.
Ph.D. in Human Genetics, Genetic Epidemiology, or a related discipline.
1-5 years experience in the biopharmaceutical industry applying human genetics to drive drug discovery and development.
Familiarity with publicly available genomic / genetic / phenotypic data sources, such as dbGaP, 1000 Genomes, GTEx, gnomAD, etc.
Experience as a member of drug discovery project teams and a demonstrated track record of effectively communicating genetic findings as it relates to project decision-making is required. To the extent that it supports effective communication in this area, a background in biology, pharmacology, chemistry, or another related field may be preferred.
Experience collaborating with top research groups worldwide in the genetics of neurological diseases as well as population-scale genetic research is required.
Experience working on genetics of cellular, molecular, and imaging-based biomarkers is highly preferred.
Familiarity with a variety of therapeutic modalities, including small molecule, ASO, antibody-based therapeutics, gene therapy, etc. is preferred.
Excellent oral and written communication skills and the ability to function as a productive member of cross-disciplinary teams is required.
Excellent organizational and management skills are required.
The ability to thrive in a flexible, goal-oriented environment is required.
Eisai requires all new hires to be fully vaccinated against COVID-19 and provide valid proof of vaccination as of their start date, to the extent permitted under state law. This requirement is a condition of employment at Eisai, and it applies regardless of whether the position is located at an Eisai site, field based or is fully remote. If you are unable to receive the vaccine due to a medical condition (including pregnancy-related), or because of your sincerely held religious beliefs, you will have an opportunity to request a reasonable accommodation
Eisai is an equal opportunity employer and as such, is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability or veteran status. Similarly, considering the need for reasonable accommodations, Eisai prohibits discrimination against persons because of disability, including disabled veterans.
Eisai Inc. participates in E-Verify. E-Verify is an Internet based system operated by the Department of Homeland Security in partnership with the Social Security Administration that allows participating employers to electronically verify the employment eligibility of all new hires in the United States. Please click on the following link for more information: